Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar
Lawmakers have emphasized gaps between U.S. list prices and overseas costs for a handful of drugs made by the three drugmakers.